Literature DB >> 22569786

Conditional probability of long-term survival in glioblastoma: a population-based analysis.

Derek R Johnson1, Daniel J Ma, Jan C Buckner, Julie E Hammack.   

Abstract

BACKGROUND: Advances in glioblastoma care have resulted in a larger proportion of patients surviving beyond 2 years after diagnosis. It is not clear how long-term survivors should be counseled with respect to future prognosis, or what factors influence that prognosis. The conditional probability of survival was evaluated from multiple time points in patients with glioblastoma, using Surveillance, Epidemiology, and End Results (SEER) data.
METHODS: Patients diagnosed with glioblastoma from 1998 to 2008 who were treated with radiation-containing regimens were identified within SEER data. Conditional survival probabilities from multiple survival points were calculated. Cox proportional hazards models were constructed to identify predictors of survival from diagnosis and from 1 and 2 years after diagnosis.
RESULTS: A total of 10,022 patients with glioblastoma met study inclusion criteria; median survival was 12.61 months. Conditional probability of surviving an additional 2 years ranged from 19.8% at diagnosis to 65.9% at 5 years after diagnosis. The proportion of patients surviving 12 months from time of diagnosis as well as from 6, 12, and 18 months after diagnosis was significantly higher in patients diagnosed in 2005 through 2008 than those diagnosed in 1998 through 2004. Of demographic and treatment-related factors evaluated, only age was associated with hazard of death at diagnosis and 1 and 3 years after diagnosis (P < .0001 at each time point).
CONCLUSIONS: Patients surviving past 2 years from diagnosis have a relatively favorable conditional probability of survival into the future compared to newly diagnosed patients. This effect becomes more pronounced with increasing time since diagnosis. These data will assist in the counseling of glioblastoma survivors.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22569786     DOI: 10.1002/cncr.27590

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

Review 1.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 2.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

3.  Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008.

Authors:  Y Yuan; J Ross; Q Shi; F G Davis
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

4.  Feasibility Testing and Refinement of a Supportive Educational Intervention for Carers of Patients with High-Grade Glioma - a Pilot Study.

Authors:  Georgia K B Halkett; Elizabeth A Lobb; Lisa Miller; Thérèse Shaw; Rachael Moorin; Anne Long; Anne King; Jenny Clarke; Stephanie Fewster; Anna K Nowak
Journal:  J Cancer Educ       Date:  2018-10       Impact factor: 2.037

Review 5.  Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.

Authors:  Divya Khosla
Journal:  Ann Transl Med       Date:  2016-02

Review 6.  Cell-based immunotherapy against gliomas: from bench to bedside.

Authors:  M Sarah S Bovenberg; M Hannah Degeling; Bakhos A Tannous
Journal:  Mol Ther       Date:  2013-05-07       Impact factor: 11.454

Review 7.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

8.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

9.  Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells.

Authors:  Eun Ho Kim; Yunhui Jo; Sei Sai; Mung-Jin Park; Jeong-Yub Kim; Jin Su Kim; Yeon-Joo Lee; Jae-Min Cho; Seo-Young Kwak; Jeong-Hwa Baek; Youn Kyoung Jeong; Jie-Young Song; Myonggeun Yoon; Sang-Gu Hwang
Journal:  Oncogene       Date:  2019-08-02       Impact factor: 9.867

10.  Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Caroline Chung; Barbara-Ann Millar; Arjun Sahgal; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-29       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.